A potential nanomedicine consisting of heparin-loaded polysaccharide nanocarriers for the treatment of asthma.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Macromolecular Bioscience

• Publication date

  2012-02-01

• Fields of study

  Medicine, Materials Science, Chemistry

• Identifiers
  DOI 10.1002/mabi.201100102PMID 22109995
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhaled drug therapy for treatment of tuberculosis.

  2011cited by this paper
• Micro- and nanocarrier-mediated lung targeting

  2010cited by this paper
• New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules.

  2009cited by this paper
• Ionically crosslinked chitosan nanoparticles as gene delivery systems: effect of PEGylation degree on in vitro and in vivo gene transfer.

  2009cited by this paper
• Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma.

  2009cited by this paper
• Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery.

  2009cited by this paper
• Nanoparticles for nasal vaccination.

  2009cited by this paper
• Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro.

  2009cited by this paper
• Inhalative nanomedicine—Opportunities and challenges

  2009cited by this paper
• Nanoparticles as protein and gene carriers to mucosal surfaces.

  2008cited by this paper
• Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system.

  2007cited by this paper
• Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides.

  2007cited by this paper
• Aerosol delivery of urocanic acid–modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice

  2006cited by this paper
• Targeted gene delivery with trisaccharide-substituted chitosan oligomers in vitro and after lung administration in vivo.

  2006cited by this paper
• A miniaturized nebulization catheter for improved gene delivery to the mouse lung

  2005cited by this paper
• Pulmonary DNA vaccination: Concepts, possibilities and perspectives

  2005cited by this paper
• Transmucosal macromolecular drug delivery.

  2005cited by this paper
• Non-invasive pulmonary aerosol delivery in mice by the endotracheal route.

  2005cited by this paper
• The occurrence of rare rpoB mutations in rifampicin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait.

  2005cited by this paper
• Nanoparticles as carriers for nasal vaccine delivery

  2005cited by this paper
• Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.

  2005cited by this paper
• Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis.

  2004cited by this paper
• Chitosan Nanoparticles as New Ocular Drug Delivery Systems: in Vitro Stability, in Vivo Fate, and Cellular Toxicity

  2004cited by this paper
• PLGA–PEI nanoparticles for gene delivery to pulmonary epithelium

  2004cited by this paper
• Cationic poly(lactide-co-glycolide) nanoparticles as efficient in vivo gene transfection agents.

  2004cited by this paper
• Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.

  2004cited by this paper
• Alternate treatments in asthma.

  2003cited by this paper
• Ouabain-induced enhancement of rat mast cells response. Modulation by protein phosphorylation and intracellular pH.

  2001cited by this paper
• Advances in immunopharmacology of asthma.

  2000cited by this paper
• Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan.

  2000cited by this paper
• Molecular-weight-dependent effects of nonanticoagulant heparins on allergic airway responses.

  1999cited by this paper
• Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin.

  1999cited by this paper
• Inhibition of allergic airway responses by inhaled low-molecular-weight heparins: molecular-weight dependence.

  1998cited by this paper
• Inhibition of antigen-induced acute bronchoconstriction, airway hyperresponsiveness, and mast cell degranulation by a nonanticoagulant heparin: comparison with a low molecular weight heparin.

  1997cited by this paper
• Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers.

  1997cited by this paper
• Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers

  1997cited by this paper
• Time course of the protective effect of inhaled heparin on exercise-induced asthma.

  1996cited by this paper
• Heparin prevents antigen-induced airway hyperresponsiveness: interference with IP3-mediated mast cell degranulation?

  1994cited by this paper
• Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin.

  1993cited by this paper
• Immunologic mast cell-mediated responses and histamine release are attenuated by heparin.

  1992cited by this paper
• The effect of concentration on the binding of compound 48/80 to rat mast cells: a fluorescence microscopy study.

  1981cited by this paper

• Treatment of lung diseases via nanoparticles and nanorobots: Are these viable alternatives to overcome current treatments?

  2025cites this paper
• Advances in Chitosan-Based Nanocarriers in the Treatment of Atopic Diseases

  2025cites this paper
• Advances in Polysaccharide-Based Formulations for Intranasal Drug Delivery: A Review

  2024cites this paper
• Recent Advances in Nanomaterials for Asthma Treatment

  2022cites this paper
• Dose-Dependent Efficacy of Umbelliferone and Gelatin-Coated ZnO/ZnS Core-Shell Nanoparticles: A Novel Arthritis Agent for Severe Knee Arthritis

  2022influential citation
• Nanosystems as curative platforms for allergic disorder management.

  2021cites this paper
• The key role of the drug self-aggregation ability to obtain optimal nanocarriers based on aromatic-aromatic drug-polymer interactions.

  2021cites this paper
• Aerosolized hyaluronic acid decorated, ferulic acid loaded chitosan nanoparticle: A promising asthma control strategy.

  2020cites this paper
• The Possible Uses and Challenges of Nanomaterials in Mast Cell Research

  2020cites this paper
• Nanoparticles and immune cells.

  2019cites this paper
• Simple Extraction Cum RP-HPLC Method for Estimation of Nanotized Quercetin in Serum and Tissues of Mice

  2018cites this paper
• Heparin: new life for an old drug.

  2017cites this paper
• Inhaled Heparin: Therapeutic Efficacy and Recent Formulations

  2017cites this paper
• Reversion of Asthmatic Complications and Mast Cell Signalling Pathways in BALB/c Mice Model Using Quercetin Nanocrystals.

  2016cites this paper
• Alternative approaches for the treatment of airway diseases: focus on nanoparticle medicine

  2016cites this paper
• Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy.

  2016cites this paper
• Aluminum-doped zinc oxide nanoparticles attenuate the TSLP levels via suppressing caspase-1 in activated mast cells

  2016cites this paper
• Nano(Neuro)Medicinal Interventions for Neurodegenerative Disorders: A Meta-Analysis of Concurrent Challenges and

  2016cites this paper
• Nanocarriers in Improved Heparin Delivery: Recent Updates.

  2015cites this paper
• Organic and Inorganic Nanoparticles for Prevention and Diagnosis of Gastric Cancer.

  2015cites this paper
• Chitosan–Cyclodextrin Complexes: Gene–Drug Delivery

  2015cites this paper
• Zinc oxide nanoparticles, a novel candidate for the treatment of allergic inflammatory diseases.

  2014cites this paper
• Low-Molecular-Weight Heparin (LMWH)–Loaded Large Porous PEG-PLGA Particles for the Treatment of Asthma

  2014cites this paper
• Nanocarriers for respiratory diseases treatment: recent advances and current challenges.

  2014cites this paper
• A micro- and nano-structured drug carrier based on biocompatible, hybrid polymeric nanoparticles for potential application in dry powder inhalation therapy

  2014cites this paper
• In Vivo Evaluation of Acute and Chronic Nanotoxicity

  2014cites this paper
• The impact of preparation parameters on typical attributes of chitosan-heparin nanohydrogels: particle size, loading efficiency, and drug release

  2013cites this paper
• Cyclodextrins as “smart” components of polymer nanoparticles

  2012cites this paper
• Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against antigen-mediated airway hyper-reactivity and inflammation.

  2012cites this paper
• Recent Advancements in the Usage of Polymeric Nanoparticles for Asthma Treatment

  year unknowncites this paper